226 related articles for article (PubMed ID: 19592311)
1. Disease progression meta-analysis model in Alzheimer's disease.
Ito K; Ahadieh S; Corrigan B; French J; Fullerton T; Tensfeldt T;
Alzheimers Dement; 2010 Jan; 6(1):39-53. PubMed ID: 19592311
[TBL] [Abstract][Full Text] [Related]
2. Modeling Alzheimer's disease progression using the disease system analysis approach.
Gomeni R; Simeoni M; Zvartau-Hind M; Irizarry MC; Austin D; Gold M
Alzheimers Dement; 2012 Jan; 8(1):39-50. PubMed ID: 21782528
[TBL] [Abstract][Full Text] [Related]
3. Quantification of disease progression and dropout for Alzheimer's disease.
William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
[TBL] [Abstract][Full Text] [Related]
4. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
5. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
6. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
7. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
[TBL] [Abstract][Full Text] [Related]
8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
9. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
Bernick C; Cummings J; Raman R; Sun X; Aisen P
Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
11. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
12. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
13. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
[TBL] [Abstract][Full Text] [Related]
14. What is the clinically relevant change on the ADAS-Cog?
Schrag A; Schott JM;
J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):171-3. PubMed ID: 22019547
[TBL] [Abstract][Full Text] [Related]
15. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
16. Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease.
Ritchie CW; Khandker RK; Pike J; Black CM; Jones E; Ambegaonkar BM
J Alzheimers Dis; 2018; 64(3):899-910. PubMed ID: 29966202
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
19. Current Alzheimer's disease clinical trials: methods and placebo outcomes.
Schneider LS; Sano M
Alzheimers Dement; 2009 Sep; 5(5):388-97. PubMed ID: 19751918
[TBL] [Abstract][Full Text] [Related]
20. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
